Published on 20 Feb 2017
Tim
Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells
Proactive the company's posted a maiden profit after receiving the first
payments from licensing lead product, a Chk1 inhibitor cancer
candidate, to Sierra Oncology.
No comments:
Post a Comment